Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update
Imad M. Tleyjeh, Zakariya Kashour, Muhammad Riaz, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 8, pp. 1076-1082
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: A systematic review and meta‐analysis
Jingwen Peng, Meihua Fu, Huan Mei, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 3
Open Access | Times Cited: 76
Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review
Fatemeh Sodeifian, Zahra Sadat Seyedalhosseini, Naghmeh Kian, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 61
Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
Su‐Yeon Yu, Dae-Hyup Koh, Miyoung Choi, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1154-1165
Open Access | Times Cited: 32
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
Fatma Haddad, Ghadeer Dokmak, Rafik Karaman
Life (2022) Vol. 12, Iss. 11, pp. 1758-1758
Open Access | Times Cited: 22
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: a meta-analysis of randomized controlled trials
Qinxue Liu, Fengjie Ma, Yizhi Zhong, et al.
Stem Cell Research & Therapy (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 11
Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS)
Beatriz Marinho Silva Romão, Felipe Vieira Duval, Elisângela da Costa Lima, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Consequences of COVID-19 on Adipose Tissue Signatures
Sontje Krupka, Anne Hoffmann, Mariami Jasaszwili, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2908-2908
Open Access | Times Cited: 4
Effect of tocilizumab plus corticosteroid on clinical outcome in patients hospitalized with severe fever with thrombocytopenia syndrome: A randomized clinical trial
Honghan Ge, Ning Cui, Xiaohong Yin, et al.
Journal of Infection (2024) Vol. 89, Iss. 1, pp. 106181-106181
Open Access | Times Cited: 4
Tocilizumab for Patients with Severe Fever with Thrombocytopenia Syndrome: Tocilizumab Observational SFTS Study-1
Jeong Rae Yoo, Mi-Sun Kim, Myeong Jin Kang, et al.
Yonsei Medical Journal (2025) Vol. 66
Open Access
¿Qué factor predice mejor el pronóstico en pacientes con COVID-19: los biomarcadores analíticos o la relación PaO2/FiO2?
Manel Rubio-Rivas, José María Mora‐Luján, Abelardo Montero Sáez, et al.
Revista Clínica Española (2025)
Closed Access
Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes
Jacopo Sabbatinelli, Giulia Matacchione, Angelica Giuliani, et al.
Mechanisms of Ageing and Development (2022) Vol. 204, pp. 111667-111667
Open Access | Times Cited: 16
Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID‐19 Pneumonia: A Single‐Center Retrospective Study
Amanda Rădulescu, Alexandru Istrate, Monica Muntean
International Journal of Infectious Diseases (2022) Vol. 117, pp. 1-7
Open Access | Times Cited: 13
Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19
Rafael San Juan, Mario Fernández‐Ruiz, Francisco López‐Medrano, et al.
International Journal of Infectious Diseases (2022) Vol. 117, pp. 56-64
Open Access | Times Cited: 12
Methodological quality and reporting quality of COVID-19 living systematic review: a cross-sectional study
Jiefeng Luo, Zhe Chen, Dan Liu, et al.
BMC Medical Research Methodology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis
Lili Luo, Ting Luo, Mengyi Du, et al.
Journal of Infection (2021) Vol. 84, Iss. 3, pp. 418-467
Open Access | Times Cited: 12
Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya
Reena Shah, Jasmit Shah, Jaimini Gohil, et al.
International Journal of General Medicine (2022) Vol. Volume 15, pp. 2415-2425
Open Access | Times Cited: 7
The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers
Manuel Rubio‐Rivas, José María Mora‐Luján, Abelardo Montero, et al.
Journal of General Internal Medicine (2021) Vol. 37, Iss. 1, pp. 168-175
Open Access | Times Cited: 9
Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry
Manuel Rubio‐Rivas, José María Mora‐Luján, Francesç Formiga, et al.
Internal and Emergency Medicine (2022) Vol. 17, Iss. 4, pp. 1115-1127
Open Access | Times Cited: 6
Clinical characteristics and factors associated with ICU mortality during the first year of the SARS-Cov-2 pandemic in Romania
Şerban-Ion Bubenek-Turconi, Ștefan Andrei, Liana Văleanu, et al.
European Journal of Anaesthesiology (2022)
Closed Access | Times Cited: 6
Inflammation in COVID-19: A Risk for Superinfections
Mariana Boulos, Tamara Bassal, Asad Layyous, et al.
COVID (2022) Vol. 2, Iss. 11, pp. 1609-1624
Open Access | Times Cited: 6
Living systematic reviews: aims and standards
Mical Paul, Mariska Leeflang
Clinical Microbiology and Infection (2023) Vol. 30, Iss. 3, pp. 265-266
Open Access | Times Cited: 3
Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials
Faezeh Ghaempanah, Maziar Nikouei, Mojtaba Cheraghi, et al.
Journal of Pharmaceutical Policy and Practice (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study
Khalid Al Sulaiman, Ohoud Aljuhani, Khalid Bin Salah, et al.
Journal of Critical Care (2021) Vol. 66, pp. 44-51
Open Access | Times Cited: 7
Characteristics of Living Systematic Review for COVID-19
Zhe Chen, Jiefeng Luo, Siyu Li, et al.
Clinical Epidemiology (2022) Vol. Volume 14, pp. 925-935
Open Access | Times Cited: 4
Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19—A narrative review
Manish Dhawan, Kuldeep Dhama, Manisha Parmar, et al.
Journal of Applied Pharmaceutical Science (2021)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top